Capsule Endoscopy in Newly Diagnosed Patients of Celiac Disease

Celiac Disease Clinical Trial

Official title:

Extent of Small Bowel Involvement on Capsule Endoscopy in Newly Diagnosed Patients of Celiac Disease

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03731806
• Other study ID #: CAP-CELIAC
• Status: Withdrawn
• Start date: April 2019
• Est. completion date: April 2020

Study information

• Verified date: February 2019
• Source: Dow University of Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Celiac Disease is an autoimmune disorder that affects approximately 1% of the world's population 1. The diagnosis of CD requires clinical, histopathological and serological factors 2. Since upper gastrointestinal endoscopy allows only visualization of the small bowel up to the second part of duodenum therefore this study was designed to determine involvement of different segments of small bowel using endoscopic scale by Bonatto MW et al 3 in newly diagnosed patients of celiac disease.

Description:

This cross sectional observational study will take place in Medical Unit-II Ruth KM Pfau Civil Hospital Karachi, Pakistan. All newly diagnosed patients of celiac disease between the ages of 8 & 60 years and patients who are currently not on gluten free diet will be included. Patients having intestinal obstruction, strictures, fistulae, dysphagia, pregnant females will be excluded. Patients having cardiac pacemakers or other implanted electromedical devices and those who are unable to swallow the capsule will also be excluded. All patients meeting inclusion criteria will be included. Informed consent will be taken from ethics committee. Patients will be provided proper brief information of procedure and confidentiality of the patients will be ensured. Patients will be advised to start clear liquid diet for 24 hours before the procedure. They will be advised to drink Movcol powder 10 sachet in 500ml of water within 20 mins, 12 hours before the procedure. They will be kept nil orally for 08 hours before the procedure. Syrup Infacol (simethicone) 15ml diluted in 50 ml of water will be given 30 mins before the procedure. Patients will be asked to swallow the capsule with 200 ml of water. Patients will be allowed to take food 4 after ingestion of capsule. All patients will be provided with capsule retrieval kit from stool. Patients will be explained to pass any stool after ingestion of capsule till it passed in stool or up to 7 days whichever is earlier. Capsule retrieved will be brought back to investigators for data retrieval from capsule. Reporting will be done by person trained to interpret capsule endoscopy. This will include presence of any pathology, its severity, approximate length and segment of small intestine involved and quality of bowel preparation. Categorical data will be presented as frequency and percentage, e.g., gender, findings of capsule endoscopy like, bowel preparation, mosaic pattern,ulcers, erythema, telangiectasia etc. Quantitative data will be presented as mean with standard deviation, e.g., age. Involvement of different segments of small intestine (duodenum, jejunum and Ileum) will be documented. Categorical data will be compared on gender by Chi-square test and quantitative data will be analyzed by student's t-test. Significance level will be set at ≤0.05.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 2020
• Est. primary completion date: March 2020
• Gender: All
• Age group: 8 Years to 60 Years

Eligibility

Inclusion Criteria:

1. All newly diagnosed patients of celiac disease between the ages of 8 & 60 years.

2. Patients who are currently not on gluten free diet.

Exclusion Criteria:

1. Patients having intestinal obstruction, strictures, fistulae, dysphagia will be excluded.

2. Pregnant females will be excluded.

3. Patients having cardiac pacemakers or other implanted electromedical devices.

4. Unable to swallow capsule.

Related Conditions & MeSH terms

• Celiac Disease

Locations

Country	Name	City	State
Pakistan	Ruth KM Pauf Civil Hospital	Karachi	Sindh

Sponsors (1)

Lead Sponsor	Collaborator
Tazeen Rasheed

Country where clinical trial is conducted

Pakistan, 

References & Publications (3)

Bonatto MW, Kotze L, Orlandoski M, Tsuchyia R, de Carvalho CA, Lima D, Kurachi G, Orso IR, Kotze L. Endoscopic evaluation of celiac disease severity and its correlation with histopathological aspects of the duodenal mucosa. Endosc Int Open. 2016 Jul;4(7):E767-77. doi: 10.1055/s-0042-108190. Epub 2016 Jun 29. — View Citation

Luján-Sanchis M, Pérez-Cuadrado-Robles E, García-Lledó J, Juanmartiñena Fernández JF, Elli L, Jiménez-García VA, Egea-Valenzuela J, Valle-Muñoz J, Carretero-Ribón C, Fernández-Urién-Sainz I, López-Higueras A, Alonso-Lázaro N, Sanjuan-Acosta M, Sánchez-Ceballos F, Rosa B, González-Vázquez S, Branchi F, Ruano-Díaz L, Prieto-de-Frías C, Pons-Beltrán V, Borque-Barrera P, González-Suárez B, Xavier S, Argüelles-Arias F, Herrerías-Gutiérrez JM, Pérez-Cuadrado-Martínez E, Sempere-García-Argüelles J. Role of capsule endoscopy in suspected celiac disease: A European multi-centre study. World J Gastroenterol. 2017 Jan 28;23(4):703-711. doi: 10.3748/wjg.v23.i4.703. — View Citation

Tennyson CA, Green PH. The role of capsule endoscopy in patients with nonresponsive celiac disease. Gastrointest Endosc. 2011 Dec;74(6):1323-4. doi: 10.1016/j.gie.2011.07.021. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Grading of Celiac Disease on Capsule Endoscopy using Bonatto Classification	Bonatto Endoscopic Classification of Celiac; 0 = Normal; I = Mostly regular villi, some foci, no mosaic pattern; II = Agglutinated but visible villi, mosaic pattern; III = Mosaic pattern, absence of villi	8 hours